SEC Form	4 FORM	4	UNITED) STA	TES S	SECURITIE	ES	AND	DE	КСНА	NG	E CO	MMISS	SION					
-		Washington, D.C. 20549												OMB APPROVAL					
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					EMENT OF CHANGES IN BENEFICIAL OWNER Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Culley Brian M					2. Issuer Name and Ticker or Trading Symbol <u>Lineage Cell Therapeutics</u> , <u>Inc.</u> [LCTX]									ationship of k all applical Director Officer (g	ole)	10% Owr			
(Last) 2173 SALF	(Last) (First) (Middle) 2173 SALK AVENUE, SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 03/10/2022									- X Oncer (give the Order (spechy below) President and CEO				
(Street) CARLSBAD CA 92008					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. India X	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	state)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially								ficially	Dumod							
1. Title of Security (Instr. 3) 2. Tran Date					í.		, 3 , T (2 ar) 8	3. Transaction Code (Instr. 8)		4. Secur	urities Acquired (A) sed Of (D) (Instr. 3, 4		A) or	or and 5)		Form:	Direct Indirect tr. 4)	7. Nature of ndirect Beneficial Ownership (Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, 1 Security or Exercise (Month/Day/Year) if any			Cod	isaction e (Instr.	5. Number of Derivative Securities Acquired (A)	Expi	. Date Exercisable and xpiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5) Benefic		tive Ownership ities Form:		11. Natur of Indired Beneficia Ownersh		

I	Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code	Transaction Derivative Code (Instr. Securities 8) Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Expiration Da (Month/Day/\		Securities Derivative (Instr. 3 ar		Derivative Security (Instr. 5)	Reported		of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
	Employee Stock Option (Right to Buy)	\$1.4	03/10/2022		A		1,250,000		(1)	03/10/2032	Common Shares	1,250,000	\$0.00	1,250,000	D	
	Restricted Stock Units	(2)	03/10/2022		A		300,000		(3)	(3)	Common Shares	300,000	\$0.00	300,000	D	

Explanation of Responses:

1. One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

2. Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share.

3. One-third of the shares will vest on or prior to March 9, 2023, and the second and third anniversaries of such date, upon the achievement of certain per share performance targets, calculated based on the trailing 20 trading day volume weighted average price of the Company's common stock as of the date of determination.

/s/ Brian M. Culley

03/11/2022

** Signature of Reporting Person

Date

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.